Efficacy of Low Dose Low Molecular Weight Heparin in the Treatment of Cutaneous Lichen Planus

Khan, Muneer; Shah, Mor; Khondker, Lubna; Mk, Hasan

doi:10.3329/jafmc.v9i1.18717

Cited by 4 publications

(3 citation statements)

References 4 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study revealed that 29 subjects (78.4%) presented no side‐effects, while the remaining reported local irritation, bruises and headache. However, all these inconveniences did not require particular care as they disappeared spontaneously …”

Section: Enoxaparin Sodiummentioning

confidence: 99%

Lichen planus: a comprehensive evidence‐based analysis of medical treatment

Husein‐ElAhmed

Gieler

Steinhoff

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Lichen planus (LP) is a chronic-relapsing inflammatory skin disease. Although many drugs have been used for the management of LP, some of them lack the backup by strong therapeutic evidence, while others are not suitable for some patients due to safety profile issues. The aim of this study was to review the recent status of available medical therapies for LP to help physicians make better decisions upon best medical practice while facing patients with this condition. A review of published articles on management of LP was conducted with the MEDLINE and PubMed databases. The quality of the evidence was graded as high, moderate, low or very low. A total of 1366 articles were retrieved, and 219 (16%) were included in the final analysis. Twenty-one different treatment modalities were analysed. The quality of evidence was high for topical steroid and calcineurin inhibitor, while it was moderate for oral steroids. All the other modalities reached low or very low quality of evidence. Topical steroids and calcineurin inhibitors are the current first-line therapies, while for other therapies the strength of recommendation is not so evident. Unfortunately, larger randomized, controlled trials to support the efficacy, safety and tolerability of other therapies in LP are lacking, and many of them are recommended based on studies with small sample sizes, lack of standardized outcome measures or lack of controlled duration or even in anecdotal evidence. Thus, large-scale randomized clinical trials are still warranted to establish the exact benefits of other topical treatments, phototherapy, immunosuppressant and new immunomodulators for an optimized treatment of LP.

show abstract

Section: Enoxaparin Sodiummentioning

confidence: 99%

Lichen planus: a comprehensive evidence‐based analysis of medical treatment

Husein‐ElAhmed

Gieler

Steinhoff

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…No recurrence of PHLP was noted in follow-ups performed over a period of 1 year. Khan et al (2014) treated cutaneous LP with enoxaparin for 6 weeks. They reported disease improvement in 26 out of 31 patients.…”

Section: Enoxaparinmentioning

confidence: 99%

“…An open-labeled, uncontrolled study treated 37 cases of cutaneous LP with 3 mg of enoxaparin once-weekly for 6 weeks. Complete remission was not observed in any of the patients and the reported side effects were local irritation, bruises and headache ( Khan et al, 2014 ). So far, only one randomized clinical trial investigated the efficacy of enoxaparin in patients with disseminated LP ( Iraji et al, 2013 ).…”

Section: Enoxaparinmentioning

confidence: 99%

Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports

et al. 2018

View full text Add to dashboard Cite

Lichen planus (LP) is an uncommon mucocutaneous inflammatory condition, that is immunologically mediated, typically pruritic and often recurs. The currently advocated therapies are either not highly effective or associated with severe side effects. Enoxaparin, a widely used anticoagulant, is composed of both anticoagulant and non-anticoagulant fragments. Enoxaparin is reported to have anti-inflammatory properties and it was found to be effective in LP. However, the results from clinical studies have varied substantially and, therefore, the clinical role of enoxaparin in LP remains uncertain. This review focuses on potential reasons for the reported inconsistent outcomes, as well as proposing solutions; these include identifying batch-to-batch inconsistency in the composition of enoxaparin. The potential therapeutic value of enoxaparin in LP must be explored using well-designed clinical trials, combined with experimental studies that focus on identifying the anti-inflammatory fragments of enoxaparin and elucidating the mechanism of action of these non-anticoagulant fragments.

show abstract